Related Experiment Video
Updated: May 7, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials
Sanjay Srivatsan1, Jaina M Patel1, Erica N Bozeman1
1Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA.
Abstract:
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.
Insights
Allogeneic cancer immunotherapies show promise for treating cancer by presenting tumor-associated antigens (TAAs). Clinical trials reveal challenges due to tumor heterogeneity, guiding future immunotherapy development.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer's high mortality and treatment resistance necessitate novel therapies.
- Tumor-associated antigens (TAAs) drive the development of anti-cancer immunotherapies.
- Allogeneic cancer cell lines offer a practical approach for inducing antitumor immunity.
Purpose of the Study:
- To review clinical trials of allogeneic tumor immunotherapies across various cancer types.
- To assess the efficacy and limitations of current allogeneic immunotherapy strategies.
- To provide insights for the future design of enhanced allogeneic immunotherapies.
Main Methods:
- Literature review of clinical trials involving allogeneic cancer immunotherapies.
- Analysis of data from studies investigating TAA presentation for antitumor immunity.
- Examination of factors contributing to treatment success or failure in clinical settings.
Main Results:
- Clinical trials have demonstrated limited success for allogeneic tumor immunotherapies to date.
- Tumor heterogeneity (inter- and intra-tumoral) is a significant challenge impacting treatment efficacy.
- Allogeneic immunotherapies are recognized for their ease of production and clinical availability.
Conclusions:
- Current clinical results underscore the need for improved allogeneic immunotherapy designs.
- Addressing tumor heterogeneity is crucial for enhancing the effectiveness of these therapies.
- Future strategies should focus on optimizing allogeneic immunotherapies as monotherapies or in combination treatments.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy